| Identification | Back Directory | [Name]
9H-Pyrido[2,3-b]indole-7-carboxamide, 5-[3-(ethylsulfonyl)phenyl]-3,8-dimethyl-N-(1-methyl-4-piperidinyl)-, hydrochloride (1:1) | [CAS]
934542-50-4 | [Synonyms]
| [Molecular Formula]
C28H32N4O3S.ClH | [MOL File]
934542-50-4.mol | [Molecular Weight]
541.11 |
| Hazard Information | Back Directory | [Uses]
TAK-901 hydrochloride is a multi-targeted aurora inhibitor with IC50s of 21 and 15 nM for aurora A and B, respectively[1]. | [in vivo]
TAK-901 (In A2780 and AML MV4-11 nude mice xenograft model) causes tumor stasis for 30 days at 30 and 40
mg/kg/injection, respectively[1].
| [IC 50]
Aurora B: 15 nM (IC50); Aurora A: 21 nM (IC50) | [References]
[1] Farrell P, et al. Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor. Mol Cancer Ther. 2013 Apr;12(4):460-70. DOI:10.1158/1535-7163.MCT-12-0657 |
|
|